A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)

Overview

Información sobre este estudio

Phase I Dose Escalation: Primary objective is to determine the MTD and the recommended dose for Phase I Extension. Secondary objective is to investigate the safety, pharmacokinetics and efficacy of BI 836858 in combination with decitabine Phase I Extension: Primary objective is to collect additional data on safety, pharmacokinetics and efficacy and to define the Recommended Phase II Dose (RP2D) of BI 836858 in combination with decitabine. Phase II: Primary objective is to investigate efficacy, safety and pharmacokinetics of BI 836858 in combination with decitabine compared to decitabine monotherapy.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Phase I Dose Escalation:
    • Male or female patients >/= 18 years of age with relapsed or refractory AML;
    • Male or female patients >/= 65 years of age with previously untreated AML ineligible for receiving standard intensive therapy.
  • Phase I Extension and Phase II:
    • Male or female patients >/= 65 years of age with previously untreated AML ineligible for receiving standard intensive therapy;
    • Histologically or cytologically confirmed AML according to the WHO classification;
    • Patients must be eligible for treatment with decitabine;
    • Eastern co-operative oncology group (ECOG) performance score.

Exclusion Criteria:

  • Acute promyelocytic leukemia (APL, French-American-British (FAB) subtype M3), according to WHO classification.
  • Patients who are candidates for allogeneic stem cell transplantation.
  • Active chronic graft versus host disease requiring immunosuppressive treatment.
  • Phase I extension and Phase II only: Prior treatment with a hypomethylating agent, such as prior treatment for MDS.
  • Prior treatment with Cluster of differentiation 33 (CD33) antibody Further exclusion criteria apply.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Jacksonville, Fla.

Investigador principal de Mayo Clinic

James Foran, M.D.

Cerrado para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publicaciones

Publications are currently not available
.
CLS-20316363

Mayo Clinic Footer